Data on persistence of NS5A resistance-associated substitutions (RASs) may have implications for resistance testing approaches and selection of initial and retreatment strategies.
Methods
Long-term persistence of NS5A RASs in HCV genotype (GT) 1 infected subjects (n=76) who did not achieve sustained virological response after receiving ledipasvir (LDV) without sofosbuvir (SOF) and were subsequently enrolled in an ongoing 3-year follow-up registry study was investigated by population or deep sequencing.
Results
Of the 76 subjects enrolled, 67 and 9 subjects had GT1a and GT1b infection, respectively. At pretreatment, NS5A RASs were detected in 14% of subjects (11/76) by population sequencing, with three subjects having >1 RAS. All RASs that were detected at pretreatment persisted and were observed at the 96 week visit in the follow-up study (FU96). For the remaining subjects with no detectable RASs at pretreatment, RASs were detected in 98% (63/64) of subjects at virological failure in the parent study and persisted at detectable levels through FU96 in 86% of subjects by deep sequencing (1% cutoff). However, a decline in the quasispecies frequency of most RASs and the number of RASs per subject was observed over time. Phenotypic analysis demonstrated that the majority of NS5A RASs confer similar levels of resistance to LDV and daclatasvir.
Conclusions
The majority of NS5A RASs can persist at detectable levels for >96 weeks post-treatment in subjects who failed treatment with regimens containing an NS5A inhibitor without SOF, suggesting relatively high fitness of NS5A RASs even in the absence of drug pressure.
References
1.
Mohd HanafiahK., GroegerJ., FlaxmanA.D., WiersmaS.T.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.Hepatology2013; 57: 1333–1342.
2.
The Polaris Observatory HCV Collaborators.Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet2017; 2: 161–176.
3.
DubuissonJ.Hepatitis C virus proteins.World J Gastroenterol2007; 13: 2406–2415.
4.
LiangT.J., GhanyM.G.Current and future therapies for hepatitis C virus infection.N Engl J Med2013; 368: 1907–1917.
5.
KanekoT., TanjiY., SatohS.Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome.Biochem Biophys Res Commun1994; 205: 320–326.
6.
HeY., StaschkeK.A., TanS.L.HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: TanS.L., editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk, UK: Horizon Bioscience2006.
7.
LawitzE.J., GruenerD., HillJ.M.A Phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.J Hepatol2012; 57: 24–31.
8.
FridellR.A., QiuD., WangC., ValeraL., GaoM.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob Agents Chemother2010; 54: 3641–3650.
9.
DeGoeyD.A., RandolphJ.T., LiuD.Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.J Med Chem2014; 57: 2047–2057.
10.
LawitzE., GaneE., PearlmanB.Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label Phase 2 trial.Lancet2015; 385: 1075–1086.
11.
AfdhalN., ReddyK.R., NelsonD.R.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.N Engl J Med2014; 370: 1483–1493.
12.
LawitzE., PoordadF.F., PangP.S.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, Phase 2 trial.Lancet2014; 383: 515–523.
13.
SulkowskiM.S., JacobsonI.M., NelsonD.R.Daclatasvir plus sofosbuvir for HCV infection.N Engl J Med2014; 370: 1560–1561.
14.
SulkowskiM.S., GardinerD.F., Rodriguez-TorresM.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med2014; 370: 211–221.
15.
MannsM., PolS., JacobsonI.M.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, Phase 3, multicohort study.Lancet2014; 384: 1597–1605.
16.
KumadaH., SuzukiY., IkedaK.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Hepatology2014; 59: 2083–2091.
17.
WylesD.L., Rodriguez-TorresM., LawitzE.All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection.Hepatology2014; 60: 56–64.
18.
WongK.A., WorthA., MartinR.Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.Antimicrob Agents Chemother2013; 57: 6333–6340.
19.
ChengG., PengB., CorsaA.Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885.EASL 47th Annual Meeting. 18–22 April 2012, Barcelona, Spain. Abstract 1172.
20.
McPheeF., HernandezD., ZhouN.Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.Antivir Ther2014; 19: 479–490.
21.
KwonH.J., XingW., ChanK.Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.PLoS One2015; 10: e0122844.
22.
YoshimiS., ImamuraM., MurakamiE.Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.J Med Virol2015; 87: 1913–1920.
23.
WangC., SunJ.H., O'BoyleD.R.IIPersistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Antimicrob Agents Chemother2013; 57: 2054–2065.
24.
ThompsonA., HanS., ShiffmanM.L.GS-5885 + GS-9451 + peginterferon and ribavirin (PR) for six or twelve weeks achieves high SVR12 rates in treatment-naive genotype 1 IL28B CC patients.48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). 24–28 April 2013, Amsterdam, the Netherlands. Abstract 64.
25.
EversonG.T., Di BisceglieA.M., VierlingJ.M.Combination of the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, and pegylated interferon plus ribavirin in treatment experienced patients with genotype 1 hepatitis c infection.EASL 2013. 24–28 April 2013, Amsterdam, the Netherlands. Abstract 13.
26.
MarcellinP., MannsM.P., JanczewskaE.12 week response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon/ribavirin in treatment naive genotype 1 hepatitis c infected patients.J Hepatol2013; 58Suppl 2: S355.
27.
Clinical Trials.gov.GS-5885, GS-9451, tegobuvir and ribavirin in treatment-experienced subjects with chronic genotype 1a or 1b hepatitis C virus (HCV) infection. (Accessed 16 September 2011.) Available from https://clinicaltrials.gov/ct2/show/NCT01435226.
28.
ShihI.H., VliegenI., PengB.Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.Antimicrob Agents Chemother2011; 55: 4196–4203.
29.
LohmannV., KornerF., KochJ., HerianU., TheilmannL., BartenschlagerR.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science1999; 285: 110–113.
30.
SarrazinC., Dvory-SobolH., SvaroskaiaE.Baseline and post-baseline resistance analyses of Phase 2/3 studies of ledipasvir/sofosbuvir ± RBV.65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD). 7–11 November 2014, Boston MA, USA. Abstract 1926.
31.
BartelsD.J., SullivanJ.C., ZhangE.Z.Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.J Virol2013; 87: 1544–1553.
32.
SuzukiF., SezakiH., AkutaN.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.J Clin Virol2012; 54: 352–354.
33.
KrishnanP., TripathiR., SchnellG.Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens.EASL 50th Annual Meeting of the European Association for the Study of the Liver. 22–26 April 2015, Vienna, Austria. Abstract 0057.
34.
De FrancescoR.Molecular virology of the hepatitis C virus.J Hepatol1999; 31Suppl 2: 47–53.
35.
HwangJ., HuangL., CordekD.G.Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins.J Virol2010; 84: 12480–12491.
36.
LimP.J., ChatterjiU., CordekD.Correlation between NS5A dimerization and hepatitis C virus replication.J Biol Chem2012; 287: 30861–30873.
37.
AscherD.B., WielensJ., NeroT.L., DoughtyL., MortonC.J., ParkerM.W.Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Sci Rep2014; 4: 4765.
38.
Ross-ThrieplandD., MankouriJ., HarrisM.Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes.J Virol2015; 89: 3123–3135.
39.
ChatterjiU., BobardtM., TaiA., WoodM., GallayP.A.Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.Antimicrob Agents Chemother2015; 59: 2496–2507.
40.
AppelN., ZayasM., MillerS.Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.PLoS Pathog2008; 4: e1000035.
41.
McGivernD.R., MasakiT., WillifordS.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Gastroenterology2014; 147: 453–462.e7.
42.
GaleM.J.Jr., KorthM.J., TangN.M.Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.Virology1997; 230: 217–227.
43.
SusserS., VermehrenJ., ForestierN.Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.J Clin Virol2011; 52: 321–327.
44.
Dvory-SobolH., GontcharovaV., MillerM.D., SvarovskaiaE.S., MoH.Persistence of resistance-associated mutations after 3 days of monotherapy with NS3 protease inhibitor GS-9451 in genotype 1 hepatitis C virus patients.63rd Annual Meeting of the American Association for the Study of Liver Diseases. 9–13 November 2012, Boston, MA, USA. Abstract 804.
45.
SullivanJ.C., De MeyerS., BartelsD.J.Evolution of treatment-emergent resistant variants in telaprevir Phase 3 clinical trials.Clin Infect Dis2013; 57: 221–229.
46.
ThomasX.V., de BruijneJ., SullivanJ.C.Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.PLoS One2012; 7: e41191.
47.
HedskogC., Dvory-SobolH., GontcharovaV.Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.J Viral Hepat2015; 22: 871–881.
48.
SarrazinC., Dvory-SobolH., SvarovskaiaE.S.Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir.Gastroenterology2016; 151: 501–512.e1.
49.
LenzO., VerbinnenT., FeveryB.Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.J Hepatol2015; 62: 1008–1014.
50.
MannsM., PolS., JacobsonI.M.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, Phase 3, multicohort study.Lancet2014; 384: 1597–1605.
51.
BourlièreM., GordonS.C., RamjiA.Sofosbuvir/ velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1–6 infection: the Phase 3 POLARIS-1 Study.The Liver Meeting, AASLD. 11–15 November 2016, Boston, MA, USA. Abstract 194.
